

Appendix 4E

Preliminary final report

1. Details of reporting period

Name of entity	Cynata Therapeutics Limited
ABN	98 104 037 372
Reporting Period	Year ended 30 June 2014
Previous Corresponding Period	Year ended 30 June 2013

2. Results for announcement to the market

Key information	12 months ended 30 June 2014 \$	12 months ended 30 June 2013 \$	Increase/ (decrease) %	Amount change \$
Revenues/(losses) from ordinary activities	107,755	71,021	51.72	36,734
Loss from ordinary activities after tax attributable to members	3,039,663	915,701	231.95	2,123,962
Net loss for the period attributable to members	3,039,663	915,701	231.95	2,123,962
Net tangible asset/(deficiency) per share	0.092	0.0033		

3. Consolidated statement of profit or loss and other comprehensive income

Refer to attached consolidated financial statements.

4. Consolidated statement of financial position

Refer to attached consolidated financial statements.

5. Consolidated statement of cash flows

Refer to attached consolidated financial statements.

6. Consolidated statement of changes in equity

Refer to attached consolidated financial statements.

7. Dividends/Distributions

No dividends declared in current or prior year.

8. Details of dividend reinvestment plans

N/A

9. Details of entities over which control has been gained or lost during the period

During the financial year, the Company increased its holding in Cynata Incorporated to 100% by acquiring the 67% balance of the shares that it did not already own through the issue of 10,000,001 shares at \$0.40. Refer to the attached consolidated financial statements for more information.

10. Details of associate and joint venture entities

	Ownership interest	
	30 June 2014	30 June 2013
Cynata Incorporated (i)	100%	27%
(i) Refer to item 9 above.		

11. Any other significant information needed by an investor to make an informed assessment of the Company's financial performance and financial position

Refer to attached consolidated financial statements.

12. Foreign entities

Refer to attached consolidated financial statements.

13. Commentary on results for period and explanatory information

Cynata Therapeutics Limited and its controlled entities (the Group) incurred a net loss from operations for the financial year ended 30 June 2014 of \$3,039,663 (2013: \$915,701). At 30 June 2014, the Group had a cash balance of \$5,094,582 (2013: \$1,116,587) and net assets of \$9,854,632 (2013: \$1,642,843). The net cash outflow from operating activities for the financial year was \$1,853,693 (2013: \$765,765). During the financial year current liabilities were reduced from \$149,700 to \$71,296.

Following shareholder approval in October 2013 of a change in nature and scale of the Company's activities pursuant to the acquisition of Cynata Inc. (as described in the attached consolidated financial statements), the Group's principal activities in the course of the remainder of the financial year were the development and commercialisation of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which the Company has branded Cymerus™. Cynata's Cymerus™ technology represents an important breakthrough in stem cell product research that facilitates large-scale manufacture of MSCs from a single donor and a single donation, comparing favourably to most other MSC technologies that require multiple donors and multiple donations. This has the potential to revolutionise commercial manufacture of MSC based therapeutic products.

14. Audit

This report is based on accounts which have been audited and the audit report is included in the attached consolidated financial statements.



Dr. Ross Macdonald
Managing Director

26 August 2014